Edesa Biotech Signs Japan Licensing Agreement With Kyorin for Paridiprubart Worth Up to $146 Million
Edesa Biotech Announces Agreement with KYORIN Pharmaceutical to Develop and Commercialize Paridiprubart in Japan
Edesa Biotech Enters Collaboration And License Agreement With Kyorin Pharmaceutical For Paridiprubart In Japan; Deal Valued At $140M+ With Potential Milestone Payments
Edesa Biotech to Present at Guggenheim Healthcare Innovation Conference
Edesa Biotech Announces FDA IND Clearance for Phase 2 Vitiligo Study
Edesa Biotech Receives FDA Clearance For Its Investigational New Drug Application For Its Phase 2 Clinical Trial Of EB06 In Vitiligo
EDSA: Recruitment in Phase 2 Vitiligo Study Set to Get Underway
Edesa Biotech Stock Sinks After Fresh Capital Raise
Edesa Biotech Announces Pricing of $25.0 Million Public Offering
Edesa Biotech Announces Proposed Public Offering
Edesa Biotech Commences Common Stock Offering; Terms Undisclosed
Edesa Biotech Reports Fiscal 3rd Quarter 2026 Results
Edesa Biotech Q3 EPS $(0.60) Misses $(0.58) Estimate
EDSA: Positive Exploratory Data in Patients with AKI
Edesa Biotech Announces $3.5 Million Private Placement of Common Shares Led by CEO and Healthcare-Focused Investors
Edesa Biotech Reports Positive Exploratory Data for Paridiprubart in Patients with Acute Kidney Injury
Edesa Biotech Announces Exploratory Data For Its Anti-TLR4 Monoclonal Antibody Paridiprubart In Patients With Acute Kidney Injury And Respiratory Distress; Analyses Demonstrate Mortality Reduction
Edesa Biotech, Inc. (EDSA) Presents at Dermatology Drug Development Summit 2026 - Slideshow
EDSA: Preparing for Mid-2026 Start to Phase 2 Vitiligo Trial
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.